Last edition
News about "T-Maximum Pharmaceutical "
T-Maximum Pharmaceutical Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy
T-MAXIMUM is currently focusing on advanced-stage solid malignancies, with its lead pipeline product for recurrent high-grade glioma (rHGG) demonstrating breakthrough efficacy and manageable safety in initial clinical studies and obtained Orphan Drug Designation (ODD) from the US FDA.
T-Maximum Pharmaceutical | 09/08/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members